Lazard Capital Markets set a $75.00 price target on Gilead Sciences (NASDAQ:GILD) in a research report sent to investors on Friday morning, Analyst Ratings.Net reports.
Other equities research analysts have also recently issued reports about the stock. Analysts at Atlantic Securities upgraded shares of Gilead Sciences from a neutral rating to an overweight rating in a research note to investors on Friday. Separately, analysts at TheStreet reiterated a buy rating on shares of Gilead Sciences in a research note to investors on Tuesday, July 23rd. Finally, analysts at RBC Capital reiterated a buy rating on shares of Gilead Sciences in a research note to investors on Wednesday, July 17th. They now have a $62.00 price target on the stock.
Six analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $64.86.
Gilead Sciences (NASDAQ:GILD) traded down 0.47% on Friday, hitting $61.73. Gilead Sciences has a 52-week low of $26.75 and a 52-week high of $64.04. The stock’s 50-day moving average is currently $54.68. The company has a market cap of $94.258 billion and a price-to-earnings ratio of 34.71.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.